These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28978581)

  • 1. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.
    Way J; Drakaki A; Drexler A; Freeby M
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
    Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
    Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New onset diabetes after nivolumab treatment.
    Capitao R; Bello C; Fonseca R; Saraiva C
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29378735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.
    Mellati M; Eaton KD; Brooks-Worrell BM; Hagopian WA; Martins R; Palmer JP; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):e137-8. PubMed ID: 26116720
    [No Abstract]   [Full Text] [Related]  

  • 9. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S; Zhang Y; Sun Z; Hu J; Fang C
    Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab-induced type 1 diabetes.
    Maia A; Soares DM; Azevedo S; Pereira T; Amaral C
    J Oncol Pharm Pract; 2024 Sep; 30(6):1118-1121. PubMed ID: 38766907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab induced new-onset type 1 diabetes mellitus.
    de Carlos J; Zabalza L; Garcia J; Marti M; Ayarza-Marien X; Yoldi J
    J Oncol Pharm Pract; 2023 Jul; 29(5):1268-1270. PubMed ID: 36635950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulminating onset type 1 diabetes with positivity for anti-GAD antibody and elevated pancreatic exocrine enzyme concentrations.
    Kahara T; Takamura T; Ando H; Sakurai M; Ota T; Misaki T; Oba S; Iguchi M; Komori K; Kobayashi K
    Intern Med; 2003 Jun; 42(6):517-20. PubMed ID: 12857052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy.
    Singhal S; Patel G; Singh RB; Goyal A; Avgush K; Koka J
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35793858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of abrupt onset autoimmune type 1 diabetes mimicking fulminant type 1 diabetes.
    Makino S; Hamada S; Iwata M; Fujiwara M
    Endocr J; 2009; 56(9):1113-7. PubMed ID: 19680007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer.
    Sothornwit J; Phunmanee A; Pongchaiyakul C
    Front Endocrinol (Lausanne); 2019; 10():352. PubMed ID: 31244772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.